AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31664782
Drug: Itraconazole 200
RxNorm normalized name: itraconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Itraconazole 200 mg
Trial: 8527290
Drug: Terbinafine 250
RxNorm normalized name: terbinafine 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbinafine 250 mg
Trial: 29737494
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of 500 mg (1, 3)(1, 6)-β-glucan (BG) daily
Trial: 28430976
Drug: Reboxetine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine (8 mg single dose)
Trial: 28430976
Drug: Reboxetine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine (8 mg/day for 21 days)
Trial: 21435141
Drug: 10-mg dapagliflozin
RxNorm normalized name: dapagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mg dapagliflozin fed (high-fat meal)
Trial: 21435141
Drug: 10-mg dapagliflozin
RxNorm normalized name: dapagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-mg dapagliflozin fasted
Trial: 16827738
Drug: Titanium abutment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titanium abutment with cemented implant-supported single-tooth crown
Trial: 16827738
Drug: Gold-alloy abutment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gold-alloy abutment with cemented implant-supported single-tooth crown
Trial: 12723857
Drug: Occlusal splint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occlusal splint therapy (S), nonsteroid anti-inflammatory with orphenadrine citrate (O), and benzodiazepine (B)
Trial: 10786738
Drug: Bupivacaine 2.5
RxNorm normalized name: Sure-Amp BUPivacaine 2.5 MG/ML Injectable Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 2.5 mg/ml for infiltration of trocar sites (Group B)
Trial: 10786738
Drug: Tenoxicam 20
RxNorm normalized name: tenoxicam 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoxicam 20 mg i.v. (Group T)
Trial: 8440094
Drug: Lovastatin (up-titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin (up-titrated from 20 mg to 80 mg/day during the first 16 weeks)
Trial: 3527514
Drug: Tripamide 10
RxNorm normalized name: xipamide
DrugBank: Xipamide (DB13803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripamide 10 mg
Trial: 3527514
Drug: Tripamide 25
RxNorm normalized name: xipamide
DrugBank: Xipamide (DB13803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripamide 25 mg
Trial: 3527514
Drug: Tripamide 50
RxNorm normalized name: xipamide
DrugBank: Xipamide (DB13803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripamide 50 mg
Trial: 3527514
Drug: Tripamide 100
RxNorm normalized name: xipamide
DrugBank: Xipamide (DB13803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tripamide 100 mg
Trial: 9184268
Drug: Antidepressant drugs
RxNorm normalized name: MAO A Inhibitors, antidepressant drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant drugs
Trial: 25502581
Drug: Losartan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (100 mg orally daily for 12 months)
Trial: 25502581
Drug: Losartan (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (in vitro treatment)
Trial: 25502581
Drug: Amlodipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (10 mg orally daily for 12 months)
Trial: 25502581
Drug: Amlodipine (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (in vitro treatment)
Trial: 18268422
Drug: Oxygen therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxygen therapy applied by nasal prongs
Trial: 10695905
Drug: Opioid bolus
RxNorm normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid bolus regimen (7.5 microg x kg(‐1) fentanyl, 70% N2O, with 2.5 microg x kg(‐1) supplements as needed)
Trial: 10695905
Drug: Opioid infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Opioid infusion (Alfentanil 50 microg x kg(‐1) bolus, 1‐1.5 microg x kg(‐1) x min(‐1) infusion, 70% N2O)
Trial: 9082104
Drug: Topical cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical cefazolin (group 2)
Trial: 9082104
Drug: Intravenous cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cefazolin (group 1)
Trial: 30429144
Drug: Zero-balance goal-directed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zero-balance goal-directed fluid therapy (GDT)
Trial: 26272051
Drug: Dutasteride (low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride (low-dose 0.5 mg/day)
Trial: 26272051
Drug: Dutasteride (high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dutasteride (high-dose 2.5 mg/day)
Trial: 19490746
Drug: Psychosocial family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosocial family intervention, individual counselling and standard treatment
Trial: 19490746
Drug: Individual counselling
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual counselling and standard treatment
Trial: 17295567
Drug: Fluoxetine (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (60 mg) plus group behavioral quit‐smoking treatment for 12 weeks
Trial: 17295567
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus group behavioral quit‐smoking treatment for 12 weeks
Trial: 11350324
Drug: Bupivacaine field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine field block administered after induction but before surgery
Trial: 11350324
Drug: Bupivacaine field
RxNorm normalized name: Field mushroom
DrugBank: Field mushroom (DB15605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine field block administered after surgery but before the end of anaesthesia
Trial: 3131041
Drug: Intravenous nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nitroglycerin (NTG) at doses ranging from 10 to 120 micrograms/min (mean = 52 +/- 33 micrograms/min)
Trial: 3135734
Drug: Intravenous nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nitroglycerin (NTG)
Trial: 3131041
Drug: Sublingual NTG
RxNorm normalized name: nitroglycerin Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual NTG (0.4 mg) as a positive control
Trial: 18240348
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy plus ecabet sodium (group B)
Trial: 18240348
Drug: Standard triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard triple therapy (group A)
Trial: 16999353
Drug: Edgewise appliance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Edgewise appliance combined with flat bite plate treatment
Trial: 10816930
Drug: Referral guidelines
RxNorm normalized name: teferrol
DrugBank: Iron polymaltose (DB15763)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Referral guidelines for orthodontic treatment
Trial: 1351804
Drug: 75 mg
RxNorm normalized name: talc 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 mg tramadol hydrochloride
Trial: 1351804
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg tramadol hydrochloride
Trial: 1351804
Drug: Acetaminophen plus
RxNorm normalized name: acetaminophen / hydrocodone Oral Capsule [Ceta Plus]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen plus propoxyphene napsylate (650 mg + 100 mg)
Trial: 2693683
Drug: 1% metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% metronidazole gel
Trial: 24113254
Drug: 17-alpha hydroxyprogesterone
RxNorm normalized name: 17-alpha-hydroxyprogesterone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17-alpha hydroxyprogesterone caproate 250 mg weekly
Trial: 16236835
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate aqueous nasal spray (FPANS) 200 microg/d
Trial: 10534607
Drug: Nalbuphine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nalbuphine 5 mg, 10 mg, 20 mg
Trial: 9695717
Drug: Disulfiram (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disulfiram (500 mg oral)
Trial: 9560064
Drug: Thioridazine 75
RxNorm normalized name: Thioridazine
DrugBank: Thioridazine (DB00679)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thioridazine 75 mg (TDZ)
Trial: 9560064
Drug: Thioridazine (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thioridazine (0, 25, 50 mg)
Trial: 9560064
Drug: Thioridazine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thioridazine (75 mg)
Trial: 27720981
Drug: Alkalinised 0.75%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkalinised 0.75% ropivacaine-2% mepivacaine solution (pH 7.0)
Trial: 27720981
Drug: Standard local
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard local anaesthetic solution (0.75% ropivacaine 5ml and 2% mepivacaine 5ml, pH 5.9)
Trial: 26360446
Drug: REFOCUS intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: REFOCUS intervention (usual treatment plus REFOCUS)
Trial: 26360446
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (usual treatment alone)
Trial: 17886373
Drug: Affinoleukin added
RxNorm normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Affinoleukin added to regular treatment
Trial: 17886373
Drug: Regular treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular treatment alone
Trial: 11206236
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate dry powder inhaler (MF-DPI), 400 microg once daily in the morning (AM)
Trial: 11206236
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate dry powder inhaler (MF-DPI), 200 microg once daily in the evening (PM)
Trial: 11206236
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate dry powder inhaler (MF-DPI), 200 microg twice daily
Trial: 786353
Drug: acebutolol (Sectral)
RxNorm normalized name: acebutolol Oral Capsule [Sectral]
DrugBank: Acebutolol (DB01193)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: acebutolol (Sectral) 300 mg
Trial: 786353
Drug: practolol (Eraldin)
RxNorm normalized name: practolol
DrugBank: Practolol (DB01297)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: practolol (Eraldin) 300 mg
Trial: 31981921
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of intravenous co-amoxiclav
Trial: 23370069
Drug: Coordinated Anxiety
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coordinated Anxiety Learning and Management (CALM) collaborative care intervention (cognitive‐behavioral therapy and/or medication)
Trial: 23370069
Drug: Opioid medications
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid medications in patients with comorbid major depression
Trial: 23370069
Drug: Opioid medications
RxNorm normalized name: OPIOIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid medications in patients with pain
Trial: 21514147
Drug: docetaxel/oxaliplatin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: docetaxel/oxaliplatin (75 mg/m² on day 1 and 70 mg/m² on day 2 every 3 weeks)
Trial: 21514147
Drug: docetaxel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: docetaxel (75 mg/m² on day 1 every 3 weeks)
Trial: 18451314
Drug: tNSAIDs, glucocorticoids,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tNSAIDs, glucocorticoids, or coxibs (any inhibitor) with NT-proBNP > or = 100 ng/L
Trial: 18451314
Drug: Coxibs (alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coxibs (alone or with tNSAIDs or glucocorticoids) with NT-proBNP > or = 100 ng/L
Trial: 18451314
Drug: Two or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two or more antiinflammatory drugs with NT-proBNP > or = 100 ng/L
Trial: 18451314
Drug: NT-proBNP <100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NT-proBNP <100 ng/L across all treatment groups
Trial: 17040253
Drug: ICD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD therapy in male patients
Trial: 17040253
Drug: ICD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD therapy in female patients
Trial: 17040253
Drug: ICD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD therapy in male patients (excluding COMPANION trial)
Trial: 17040253
Drug: ICD therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICD therapy in female patients (excluding COMPANION trial)
Trial: 12943944
Drug: Serotonergic antidepressants
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonergic antidepressants (clomipramine mean dose 145 mg and fluoxetine mean dose 27 mg)
Trial: 12943944
Drug: Noradrenergic antidepressants
RxNorm normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noradrenergic antidepressants (desipramine mean dose 200 mg and nortriptyline mean dose 100 mg)
Trial: 12943944
Drug: Noradrenergic antidepressants
RxNorm normalized name: Rauwolfia alkaloids, centrally acting antiadrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noradrenergic antidepressants
Trial: 24971677
Drug: EX‐rST: combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EX‐rST: combination of EX and rST
Trial: 7661161
Drug: Triple therapy:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy: bismuth nitrate (4 x 375 mg) plus metronidazole (4 x 250 mg) and tetracycline (4 x 500 mg) daily for 2 wk and ranitidine (150 mg) for the first week and bismuth nitrate (4 x 375 mg) alone for a further 2 wk
Trial: 7661161
Drug: Omeprazole (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (2 x 40 mg) plus amoxycillin (4 x 500 mg) for 2 wk
Trial: 7661161
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg) plus amoxycillin (4 x 500 mg) and tinidazole (2 x 500 mg) for 2 wk
Trial: 2596423
Drug: Daily alternating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily alternating slimming diet
Trial: 23656173
Drug: Cerebrolysin (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cerebrolysin (Group A, once daily intravenous infusion of 30 mL Cerebrolysin over a 60‐min period for 5 days)
Trial: 23656173
Drug: Placebo (Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (Group B, same dosage and administration of normal saline as Group A)
Trial: 22248833
Drug: H5N1-AS03(A) adjuvanted
RxNorm normalized name: Influenza A monovalent (H5N1), adjuvanted, National stockpile 2013 [AS03 Adjuvant]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H5N1-AS03(A) adjuvanted formulations
Trial: 22248833
Drug: H5N1-DIL nonadjuvanted
RxNorm normalized name: influenza, H5N1-1203
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H5N1-DIL nonadjuvanted formulations
Trial: 19193660
Drug: Rapeseed oil
RxNorm normalized name: Rapeseed oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapeseed oil (1.6 g/meal) rich in n‐3 alpha‐linolenic acid (ALA)
Trial: 19193660
Drug: Commercial complementary
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Commercial complementary meals with corn oil (3.4 g/meal) rich in n‐6 linoleic acid (LA)
Trial: 10591382
Drug: 9 mg
RxNorm normalized name: fiber 469 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9 mg of intra-arterial recombinant prourokinase (r-proUK) plus heparin
Trial: 10591382
Drug: Heparin only
RxNorm normalized name: Heparin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin only (control)
Trial: 8708717
Drug: High-dose leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose leucovorin (FA) 500 mg/m2 combined with fluorouracil (FU) 500 mg/m2 (group A)
Trial: 8708717
Drug: Low-dose leucovorin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose leucovorin (FA) 20 mg/m2 combined with fluorouracil (FU) 500 mg/m2 (group B)
Trial: 1788750
Drug: Intravenous PGE1
RxNorm normalized name: PGE1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous PGE1 (60 mcg)
Trial: 6267643
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg of naloxone IV
Trial: 6267643
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of naloxone
Trial: 30280459
Drug: 100 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 μg selenium/day as selenium-enriched yeast
Trial: 30280459
Drug: 200 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 μg selenium/day as selenium-enriched yeast
Trial: 30280459
Drug: 300 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 μg selenium/day as selenium-enriched yeast
Trial: 27545511
Drug: Ibuprofen IR/ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen IR/ER 600 mg (formulation A)
Trial: 27545511
Drug: Ibuprofen IR/ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen IR/ER 600 mg (formulation B)
Trial: 15545544
Drug: 5 U
RxNorm normalized name: vitamin E 5 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 U of botulinum exotoxin A in 0.25 mL of preserved saline (2 U/0.1 mL)
Trial: 15545544
Drug: 5 U
RxNorm normalized name: vitamin E 5 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 U of botulinum exotoxin A in 0.05 mL of preserved saline (2 U/0.02 mL)
Trial: 11319508
Drug: Estriol treatment
RxNorm normalized name: Estriol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estriol treatment per vaginam
Trial: 11319508
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no estriol treatment)
Trial: 8043059
Drug: Preoperative chemotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative chemotherapy plus surgery
Trial: 3306494
Drug: labetalol (20‐80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: labetalol (20‐80 mg)
Trial: 3306494
Drug: hydralazine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydralazine (5 mg)
Trial: 22087680
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (2 g per day)
Trial: 12162602
Drug: Individualized calcium
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized calcium (Ca) and phosphorus (P) supplementation adjusted to achieve urinary excretion of > or = 1.2 mmol/L Ca and > or = 0.4 mmol/L P.
Trial: 7644079
Drug: Oral sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sumatriptan 25 mg
Trial: 7640145
Drug: Oral sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sumatriptan 50 mg
Trial: 7768259
Drug: Oral sumatriptan
RxNorm normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sumatriptan
Trial: 2787310
Drug: Lung hyperinflation
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung hyperinflation at tidal volume 12 cc/kg
Trial: 2787310
Drug: Lung hyperinflation
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung hyperinflation at tidal volume 14 cc/kg
Trial: 2787310
Drug: Lung hyperinflation
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung hyperinflation at tidal volume 16 cc/kg
Trial: 2787310
Drug: Lung hyperinflation
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung hyperinflation at tidal volume 18 cc/kg
Trial: 342359
Drug: Carbenoxolone capsules
RxNorm normalized name: carbenoxolone
DrugBank: Carbenoxolone (DB02329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbenoxolone capsules (Duogastrone, 50 mg four times a day for six weeks)
Trial: 342359
Drug: Carbenoxolone capsules
RxNorm normalized name: carbenoxolone
DrugBank: Carbenoxolone (DB02329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbenoxolone capsules
Trial: 31866104
Drug: Behaviour therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behaviour therapy for drug abusers (120 days treatment)
Trial: 31866104
Drug: Behaviour therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behaviour therapy for alcohol abusers (90 days treatment)
Trial: 31866104
Drug: Behaviour therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behaviour therapy for both groups
Trial: 28646811
Drug: Tui na
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tui na treatment (2 times/week for 10 weeks, 15 min/session)